News Release

Use of tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis and incidence of hypertension, initiation of statins

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: In this study of people taking pre-exposure prophylaxis (PrEP) for HIV, tenofovir alafenamide fumarate (TAF) use was found to be associated with higher incident hypertension and statin initiation compared with tenofovir disoproxil fumarate use, especially in those 40 years or older. Continued monitoring of blood pressure and lipids for TAF users is warranted. 

Authors: Adovich S. Rivera, M.D., Ph.D., of Kaiser Permanente Southern California in Pasadena, is the corresponding author. 

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.